Novel MMAU Auristatin Glycoside ADC Against Melanoma – Stabilised Hydrophilic Linker-Payload Provides A Wide Therapeutic Window & Improved Potency
Time: 10:30 am
day: Conference Day Two
Details:
- Review novel auristatin ADCs based on MMAU payload enable widening of therapeutic window compared to vedotin ADCs
- Discuss how high systemic and metabolic stability of cleavable glycopeptide linker improved both in vivo efficacy and tolerability
- Assess DAR4 and DAR8 MMAU ADCs against solid and heme malignancies